Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-center Phase I/II Study of NY-ESO-1 T Cell Receptor Gene Transferred T Lymphocytes in Patients with Synovial Sarcoma

Next Previous
X
Search
Trial Profile

Multi-center Phase I/II Study of NY-ESO-1 T Cell Receptor Gene Transferred T Lymphocytes in Patients with Synovial Sarcoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mipetresgene autoleucel (Primary) ; Cyclophosphamide
  • Indications Synovial sarcoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Takara Bio

    • Most Recent Events

    • 05 Dec 2023 Status changed from active, no longer recruiting to completed.
    • 06 Jun 2023 Results assessing safety and the efficacy of gene engineered autologous T cell product with NY-ESO-1 siTCR retroviral vector which expressed affinity-enhanced NY-ESO-1-specific TCR and siRNA to silence endogenous TCR, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 06 Oct 2020 Planned End Date changed from 31 Jan 2034 to 1 Jan 2034.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top